Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Ejhaem|August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma AllianceMaciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2025
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION StudyAdrian Minson, Emma Verner, Pratyush Giri, et al.
British Journal of Haematology|February 5, 2020
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patientsLasse H Jakobsen, Fredrik Ellin, Knut B Smeland, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2017
The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapyTarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
British Journal of Haematology|September 30, 2016
Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvementTarec Christoffer El-Galaly, Chan Y Cheah, Martin Hutchings, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
Haematologica|February 23, 2023
Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma AllianceAllison Barraclough, James T England, Diego Villa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare)Anthony R Mato, Matthew S Davids, Jeff Sharman, et al.
Pageof 17